NewLink higher after results posted for Phase II study of NLG207.
Shares of NewLink Genetics are higher ahead of the tomorrow's presentation at the American Association for Cancer Research's annua; meeting. Results of a Phase II study of NLG207 combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer has been posted online. The conclusion reads, "NLG207 is a potentially best-in-class topoisomerase 1 inhibitor with demonstrated antitumor activity in recurrent ovarian cancer including those who have become resistant to platinum therapy. AE profile of this combination is consistent with that seen for paclitaxel as a single agent except for cystitis, hematuria and UTI. It was well-tolerated in combination with weekly paclitaxel in heavily pre-treated patients. NLG207 warrants further investigation in combination therapy regimens for recurrent ovarian, fallopian tube or primary peritoneal cancer, particularly in platinum resistant patients." Shares of NewLink Genetics are up 9%, or 18c, to $2.11 in afternoon trading. [Reference Link]:[https://www.abstractsonline.com/pp8/#!/6812/presentation/9952]
|Printer friendly Cite/link Email Feedback|
|Date:||Apr 1, 2019|
|Previous Article:||CareDX CEO sees 'much bigger' opportunity in kidney transplant market.|
|Next Article:||Gulfport call trader covers part of short position up 87%.|